drugset / Trial / NCT05560308
Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy
NaSingle-groupOpen-labelTreatment
Summary
This trial is a combination of trastuzumab and pyrotinib in the treatment of patients with HER2-positive metastatic breast cancer who have progressed on TKI therapy. A total of 50 patients were enrolled in the study design. Preliminary efficacy and safety in patients with HER2-positive metastatic breast cancer who have progressed on TKI therapy.
Timeline
- Start
- 2022-09-30
- Primary completion
- 2024-08-31
- Completion
- 2025-08-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pyrotinib | Small molecule | 320 mg | Oral |
| Subject | Trastuzumab emtansine | Other / unclassified | 3.6 mg/kg | Intravenous |